Recommendations for genetic testing to reduce the incidence of anthracycline‐induced cardiotoxicity

AIMS: Anthracycline‐induced cardiotoxicity (ACT) occurs in 57% of treated patients and remains an important limitation of anthracycline‐based chemotherapy. In various genetic association studies, potential genetic risk markers for ACT have been identified. Therefore, we developed evidence‐based clin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Clin Pharmacol
Main Authors: Aminkeng, Folefac, Ross, Colin J. D., Rassekh, Shahrad R., Hwang, Soomi, Rieder, Michael J., Bhavsar, Amit P., Smith, Anne, Sanatani, Shubhayan, Gelmon, Karen A., Bernstein, Daniel, Hayden, Michael R., Amstutz, Ursula, Carleton, Bruce C.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2016
Assuntos:
Reviews
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5338111/
https://ncbi.nlm.nih.gov/pubmed/27197003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13008
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados